A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
Latest Information Update: 07 May 2026
At a glance
- Drugs Faricimab (Primary) ; RO 7823653 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Genentech
Most Recent Events
- 17 Apr 2026 Planned initiation date changed from 1 Apr 2026 to 22 Apr 2026.
- 19 Mar 2026 Status changed from not yet recruiting to recruiting.
- 05 Mar 2026 New trial record